Ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)
Conditions
Interventions
None listed
Sponsors
Japanese Gynecologic Oncology Group (JGOG)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Patients who can approve informed consent and sign it Patients who show their will to participate in this study and can sign the informed consent forms by themselves. 2. Patients who are clinically diagnosed as ovarian cancer and can provide written informed consent before the surgery 3. Patients who can provide tumor tissue specimens (except ascites cytology and cell block specimens) 4. Patients who are 20 years old and over at the enrollment 5. Patients with ECOG Performance status (PS): 0-2
Exclusion criteria
Exclusion criteria: 1. Patients with active concomitant malignancy* except breast cancer. *Includes synchronous multiple cancer and metachronous multiple cancer with less than 5 years of disease free survival. However, excludes skin basal cell carcinoma, skin squamous cell carcinoma, and any other curable lesions with local therapy such as carcinoma in situ or intramucosal carcinoma. 2. Patients who are diagnosed as any other acute/chronic, physically/mentally severe diseases and judged by the primary physician as inappropriate to enroll this study because of safety reasons or any influence to study outcomes. 3. Any other cases that are inappropriate to enroll this study, judged by study principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of HRD in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) | — |
Secondary
| Measure | Time frame |
|---|---|
| Association between Progression Free Survival (PFS) / Response Rate and HRD in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) Association between Progression Free Survival (PFS) / Response Rate and germline mutation in BRCA1/2 gene in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) | — |
Countries
Japan
Contacts
Public ContactKosuke Yoshihara
Niigata University Graduate School of Medical and Dental Sciences Department of Obstetrics and Gynecology
Outcome results
None listed